Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: PCK1

Gene summary for PCK1

Gene summary.

Gene information	Species	Human
	Gene symbol	PCK1
	Gene ID	5105
	Gene name	phosphoenolpyruvate carboxykinase 1
	Gene Alias	PCKDC
	Cytomap	20q13.31
	Gene Type	protein-coding
	GO ID	GO:0001101
	UniProtAcc	P35558

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
5105	PCK1	HTA11_3410_2000001011	Human	Colorectum	AD	1.87e-07	-4.85e-01	0.0155
5105	PCK1	HTA11_347_2000001011	Human	Colorectum	AD	1.21e-37	1.24e+00	-0.1954
5105	PCK1	HTA11_411_2000001011	Human	Colorectum	SER	2.43e-05	1.52e+00	-0.2602
5105	PCK1	HTA11_5212_2000001011	Human	Colorectum	AD	4.34e-08	1.14e+00	-0.2061
5105	PCK1	HTA11_10711_2000001011	Human	Colorectum	AD	5.85e-03	-4.87e-01	0.0338
5105	PCK1	HTA11_7696_3000711011	Human	Colorectum	AD	2.20e-07	-4.46e-01	0.0674
5105	PCK1	HTA11_6818_2000001021	Human	Colorectum	AD	3.57e-07	-5.71e-01	0.0588
5105	PCK1	HTA11_99999971662_82457	Human	Colorectum	MSS	4.66e-03	7.00e-01	0.3859
5105	PCK1	HTA11_99999974143_84620	Human	Colorectum	MSS	6.92e-19	-5.62e-01	0.3005
5105	PCK1	F007	Human	Colorectum	FAP	6.22e-08	-5.44e-01	0.1176
5105	PCK1	A002-C-010	Human	Colorectum	FAP	1.27e-11	-5.35e-01	0.242
5105	PCK1	A001-C-207	Human	Colorectum	FAP	1.10e-07	-4.91e-01	0.1278
5105	PCK1	A015-C-203	Human	Colorectum	FAP	2.80e-09	-3.48e-01	-0.1294
5105	PCK1	A015-C-204	Human	Colorectum	FAP	2.78e-06	-4.73e-01	-0.0228
5105	PCK1	A002-C-201	Human	Colorectum	FAP	1.39e-14	-5.20e-01	0.0324
5105	PCK1	A002-C-203	Human	Colorectum	FAP	2.09e-21	-5.60e-01	0.2786
5105	PCK1	A001-C-119	Human	Colorectum	FAP	6.58e-04	-4.49e-01	-0.1557
5105	PCK1	A001-C-108	Human	Colorectum	FAP	1.41e-15	-5.23e-01	-0.0272
5105	PCK1	A002-C-205	Human	Colorectum	FAP	3.98e-15	-5.31e-01	-0.1236
5105	PCK1	A001-C-104	Human	Colorectum	FAP	2.10e-08	-4.07e-01	0.0184

Page: 1 2 3

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
GC		CAG: Chronic atrophic gastritis
		CAG with IM: Chronic atrophic gastritis with intestinal metaplasia
		CSG: Chronic superficial gastritis
		GC: Gastric cancer
		SIM: Severe intestinal metaplasia
		WIM: Wild intestinal metaplasia
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:0048732	Colorectum	AD	gland development	149/3918	436/18723	6.07e-11	6.33e-09	149
GO:0006090	Colorectum	AD	pyruvate metabolic process	47/3918	106/18723	4.85e-08	2.55e-06	47
GO:0032868	Colorectum	AD	response to insulin	91/3918	264/18723	2.02e-07	8.48e-06	91
GO:0071383	Colorectum	AD	cellular response to steroid hormone stimulus	73/3918	204/18723	6.31e-07	2.24e-05	73
GO:1901653	Colorectum	AD	cellular response to peptide	114/3918	359/18723	8.32e-07	2.88e-05	114
GO:0009743	Colorectum	AD	response to carbohydrate	86/3918	253/18723	8.43e-07	2.90e-05	86
GO:0044282	Colorectum	AD	small molecule catabolic process	118/3918	376/18723	1.05e-06	3.55e-05	118
GO:0032869	Colorectum	AD	cellular response to insulin stimulus	72/3918	203/18723	1.10e-06	3.68e-05	72
GO:0071375	Colorectum	AD	cellular response to peptide hormone stimulus	95/3918	290/18723	1.50e-06	4.66e-05	95
GO:0043434	Colorectum	AD	response to peptide hormone	126/3918	414/18723	2.70e-06	7.86e-05	126
GO:0009062	Colorectum	AD	fatty acid catabolic process	41/3918	100/18723	4.02e-06	1.09e-04	41
GO:0034284	Colorectum	AD	response to monosaccharide	76/3918	225/18723	4.64e-06	1.23e-04	76
GO:0061008	Colorectum	AD	hepaticobiliary system development	55/3918	150/18723	6.34e-06	1.59e-04	55
GO:0001889	Colorectum	AD	liver development	54/3918	147/18723	7.20e-06	1.77e-04	54
GO:0033500	Colorectum	AD	carbohydrate homeostasis	84/3918	259/18723	9.10e-06	2.15e-04	84
GO:0009746	Colorectum	AD	response to hexose	73/3918	219/18723	1.20e-05	2.65e-04	73
GO:0031667	Colorectum	AD	response to nutrient levels	138/3918	474/18723	1.22e-05	2.68e-04	138
GO:0009749	Colorectum	AD	response to glucose	71/3918	212/18723	1.31e-05	2.85e-04	71
GO:0048545	Colorectum	AD	response to steroid hormone	104/3918	339/18723	1.33e-05	2.90e-04	104
GO:0042593	Colorectum	AD	glucose homeostasis	83/3918	258/18723	1.44e-05	3.11e-04	83

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa0001012	Liver	Cirrhotic	Glycolysis / Gluconeogenesis	32/2530	67/8465	1.50e-03	7.80e-03	4.81e-03	32
hsa0491031	Liver	Cirrhotic	Insulin signaling pathway	56/2530	137/8465	3.74e-03	1.50e-02	9.26e-03	56
hsa0415231	Liver	Cirrhotic	AMPK signaling pathway	49/2530	121/8465	7.90e-03	2.74e-02	1.69e-02	49
hsa040683	Liver	Cirrhotic	FoxO signaling pathway	52/2530	131/8465	9.98e-03	3.32e-02	2.05e-02	52
hsa0332031	Liver	Cirrhotic	PPAR signaling pathway	32/2530	75/8465	1.24e-02	3.92e-02	2.42e-02	32
hsa0492231	Liver	Cirrhotic	Glucagon signaling pathway	43/2530	107/8465	1.42e-02	4.35e-02	2.68e-02	43
hsa0002021	Liver	HCC	Citrate cycle (TCA cycle)	28/4020	30/8465	1.08e-07	1.44e-06	8.02e-07	28
hsa0491041	Liver	HCC	Insulin signaling pathway	95/4020	137/8465	1.53e-07	1.97e-06	1.10e-06	95
hsa0493121	Liver	HCC	Insulin resistance	77/4020	108/8465	3.89e-07	4.46e-06	2.48e-06	77
hsa0062021	Liver	HCC	Pyruvate metabolism	37/4020	47/8465	1.10e-05	8.03e-05	4.46e-05	37
hsa040684	Liver	HCC	FoxO signaling pathway	85/4020	131/8465	3.99e-05	2.16e-04	1.20e-04	85
hsa0415241	Liver	HCC	AMPK signaling pathway	77/4020	121/8465	2.32e-04	1.11e-03	6.18e-04	77
hsa049202	Liver	HCC	Adipocytokine signaling pathway	45/4020	69/8465	2.19e-03	7.55e-03	4.20e-03	45
hsa033204	Liver	HCC	PPAR signaling pathway	48/4020	75/8465	2.83e-03	9.37e-03	5.21e-03	48
hsa0001022	Liver	HCC	Glycolysis / Gluconeogenesis	43/4020	67/8465	4.26e-03	1.29e-02	7.15e-03	43
hsa0492241	Liver	HCC	Glucagon signaling pathway	64/4020	107/8465	6.70e-03	1.87e-02	1.04e-02	64
hsa0002031	Liver	HCC	Citrate cycle (TCA cycle)	28/4020	30/8465	1.08e-07	1.44e-06	8.02e-07	28
hsa0491051	Liver	HCC	Insulin signaling pathway	95/4020	137/8465	1.53e-07	1.97e-06	1.10e-06	95
hsa0493131	Liver	HCC	Insulin resistance	77/4020	108/8465	3.89e-07	4.46e-06	2.48e-06	77
hsa0062031	Liver	HCC	Pyruvate metabolism	37/4020	47/8465	1.10e-05	8.03e-05	4.46e-05	37

Page: 1 2 3 4 5 6

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

PCK1

SNV

Missense_Mutation

novel

c.85N>A

p.Glu29Lys

p.E29K

P35558

protein_coding

tolerated(0.59)

benign(0.003)

TCGA-A7-A4SA-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicin

PCK1

SNV

Missense_Mutation

c.689C>G

p.Ser230Cys

p.S230C

P35558

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

PCK1

SNV

Missense_Mutation

c.521N>G

p.Thr174Arg

p.T174R

P35558

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-AC-A6IX-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Unknown

PCK1

SNV

Missense_Mutation

novel

c.369N>T

p.Glu123Asp

p.E123D

P35558

protein_coding

tolerated(0.57)

benign(0)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

PCK1

SNV

Missense_Mutation

novel

c.1779N>T

p.Glu593Asp

p.E593D

P35558

protein_coding

tolerated(0.08)

benign(0)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

PCK1

SNV

Missense_Mutation

c.650C>A

p.Thr217Lys

p.T217K

P35558

protein_coding

tolerated(0.87)

benign(0.213)

TCGA-AO-A0JD-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

cyclophosphamide

PCK1

SNV

Missense_Mutation

c.584N>T

p.Ser195Phe

p.S195F

P35558

protein_coding

deleterious(0)

probably_damaging(0.998)

TCGA-B6-A1KF-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

PCK1

SNV

Missense_Mutation

c.1180N>C

p.Glu394Gln

p.E394Q

P35558

protein_coding

tolerated(0.26)

benign(0.019)

TCGA-BH-A0HK-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

arimidex

PCK1

SNV

Missense_Mutation

novel

c.715T>C

p.Ser239Pro

p.S239P

P35558

protein_coding

deleterious(0)

probably_damaging(0.973)

TCGA-C8-A1HG-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

PCK1

SNV

Missense_Mutation

novel

c.971N>T

p.Arg324Met

p.R324M

P35558

protein_coding

tolerated(0.05)

possibly_damaging(0.904)

TCGA-OL-A97C-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

Page: 1 2 3 4 5 6 7 8 9

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1